Risk evaluation and mitigation strategy for mavacamten: An example demonstrating appropriate safety oversight.

In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial.

Importance: There is limited evidence regarding early treatment of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to mitigate symptom progression.

Objective: To examine whether high-dose zinc and/or high-dose ascorbic acid reduce the severity or duration of symptoms compared with usual care among ambulatory patients with SARS-CoV-2 infection.

Design, Setting, And Participants: This multicenter, single health system randomized clinical factorial open-label trial enrolled 214 adult patients with a diagnosis of SARS-CoV-2 infection confirmed with a polymerase chain reaction assay who received outpatient care in sites in Ohio and Florida.

Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy.

Introduction: Hypertrophic cardiomyopathy (HCM) is a common known monogenetic cardiovascular disorder which frequently leads to symptoms such as dyspnea and exercise intolerance. Current guideline-recommended pharmacotherapies have variable therapeutic responses. Mavacamten, a small molecule modulator of β-cardiac myosin, reduces hypercontractility, a central mechanism in the pathogenesis of HCM.

Representation of Women in Cardiovascular Clinical Trial Leadership.

This quality improvement study describes representation of women within leadership committees of clinical trials and in lead authorship positions of ensuing cardiovascular trial publications.

IL6 plasma concentrations in patients with sepsis receiving SLED and antibiotics: a predictor for survival.

Background: The present study evaluated interleukin-6 (IL6) as a predictor of mortality in patients and sepsis with acute kidney injury (AKI) receiving sustained low-efficiency dialysis (SLED) and antibiotic therapy.

Patients And Methods: Seven patients with sepsis receiving antibiotics and SLED for AKI were studied. Blood was obtained at baseline prior to SLED and antibiotics, during SLED, and then after stopping SLED.

Socioeconomic status and comorbidity as predictors of preoperative quality of life in cardiac surgery.

Objective: Preoperative quality of life of patients undergoing cardiac surgical procedures has been associated with postoperative morbidity, survival, and quality of life. Patients of lower socioeconomic status have disproportionately greater cardiovascular disease burden and more complications of cardiovascular disease. We examined the interactive effects of demographic characteristics, socioeconomic status, and comorbidity on preoperative functional quality of life measured by the well-validated cardiovascular disease-specific Duke Activity Status Index.